GW Pharma (GWPH) Posts Smaller Q4 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/3/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2019 Financial Results and Operational Progress
February 25, 2020 4:01 PM EST- Total revenue of $109.1 million for the fourth quarter and $311.3 million for the full year -
- Total Epidiolex® net product sales of $104.5 million for the fourth quarter and $296.4 million for the first full year of sales -
- Conference call today at 4:30 p.m. ESTÂ -
LONDON and CARLSBAD, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announces financial results for the fourth... More
